$SLS· SEC filing ·

SLS Reports $71.8M Cash, $42.6M Q1 Proceeds, Advances GPS Phase 3 REGAL Trial to 80 Events, Launches SLS009 Expansion in AML

SELLAS Life Sciences Group, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $9.07

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS